New York University has teamed up with corporate-backed biopharmaceutical incubator Futurx to spawn neurodegenerative disease drug developer Glixogen Therapeutics.
Futurx, a biopharmaceutical incubator supported by pharmaceutical developers Johnson & Johnson (J&J) and Takeda Pharmaceutical, formally unveiled Israel-based Glixogen Therapeutics yesterday to design drugs based on New York University (NYU) research. Glixogen Therapeutics will specialise in treatments for neurodegenerative disorders such as multiple sclerosis, focusing on the mitigation of a process called demyelination which destroys…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
